A Phase II Trial of Regadenoson in Sickle Cell Anemia

Clinical trial NCT01788631 · COMPLETED

Trial details

NCT number: NCT01788631
Sponsor: Dana-Farber Cancer Institute
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Sickle Cell Anemia

Start date: 2013-07-01
Primary completion: 2016-11-10
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.